You are here:Home-Research Areas-Neurological Disease-Epilepsy

Request The Product List ofEpilepsy Epilepsy

Cat. No. Product Name CAS No. Information
PC-35480

Cenobamate

913088-80-9

Cenobamate (YKP-3089, YKP3089) is a potential anti-seizure agent with currently unknown mechanisms of action.

Epilepsy

Phase 3 Clinical

PC-61895

Alprazolam

28981-97-7

Alprazolam (D-65MT;U 31889) is a triazolobenzodiazepine agent with anxiolytic, sedative-hypnotic and anticonvulsant activities; binds to a specific site distinct from the inhibitory neurotransmitter GABA binding site on the benzodiazepine-GABA-A-chloride ionophore receptor complex located in the limbic, thalamic and hypothalamic regions of the central nervous system (CNS).

Epilepsy

Phase 2 Clinical

PC-35481

JNJ-26489112

871824-55-4 JNJ-26489112 (JNJ26489112) is a broad-spectrum anticonvulsant that displays activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures; exhibits very weak inhibition of human CA-II (IC50=35 μM); inhibits Na+, kainate, and KCNQ2 channels to varying degrees, while moderately potentiating GABA current and inhibiting N-methyl-D-aspartic acid current, its action at several targets appears to be responsible for the observed neurostabilizing effects; shows limited seizure spread and elevated seizure threshold in preclinical animal models.

Epilepsy

Discontinued

PC-35479

Padsevonil

1294000-61-5 Padsevonil (UCB-0942, UCB0942) is a potential anti-seizure agent that functions as a pre- and post-synaptic inhibitor.

Epilepsy

Phase 2 Clinical

PC-43391

VX-765

273404-37-8 VX-765 (Belnacasan) is an orally absorbed prodrug of VRT-043198, which is a potent and selective inhibitor of interleukin-converting enzyme/caspase-1 with Ki of 0.8 nM; VRT-043198 exhibits 100- to 10,000-fold selectivity against other caspase-3 and -6 to -9, VX-765 is converted rapidly to VRT-043198 under the action of plasma and liver esterases; inhibits LPS-induced IL-1β production, reduces disease severity and the expression of inflammatory mediators in models of rheumatoid arthritis and skin inflammation.

Epilepsy

Phase 2 Discontinued

PC-62933

CI-966

110283-79-9 CI-966 (PD 126141) is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively; displays >200-fold selectivity over GAT-2 and GAT-3; shows anticonvulsive and neuroprotective activity in vivo.

Epilepsy

Phase 1 Discontinued

PC-62932

CI-966 hydrochloride

110283-66-4 CI-966 is a potent, selective inhibitor of the GABA transporter GAT-1 with IC50 of 0.26 and 1.2 uM for human and rat GAT-1, respectively; displays >200-fold selectivity over GAT-2 and GAT-3; shows anticonvulsive and neuroprotective activity in vivo.

Epilepsy

Phase 1 Discontinued

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com